Table 3.

Survey of the monkeys involved in the reversible inactivation experiments, with indication of the number of sites infused with muscimol for each monkey and each daily session (corresponding to the inactivation of a given motor cortical area).

Motor cortical area inactivated	Control monkeys				Anti-Nogo-A antibody treated monkeys
	Mk-C-C-BI	Mk-C-C-CE*	Mk-C-C-RO	Mk-C-C-JU*	Mk-C-A-MO	Mk-C-A-VA	Mk-C-A-SL&
NUMBER OF INFUSION SITES WITH MUSCIMOL
M1	12	9	10	6	20	11	11
PMd	6	8	7	–	7	5	10
PMv	5	8	6	–	4	4	–
PMv/PMd	–	–	–	16	–	–	–
TOTAL VOLUME OF MUSCIMOL INJECTED (μl)
M1	12	9	10	6	20	11	11
PMd	7	8	7	–	7	7.5	10
PMv	5.4	8	6	–	4.4	4.4	–
PMv/PMd	–	–	–	16	–	–	–

*Two pilot monkeys taken from Ref. (32).

^&Only the contralesional hand was tested in Mk-C-A-SL.

In Mk-C-C-JU, muscimol was infused simultaneously in PMd and PMv.

The infusion of muscimol at each site took roughly 3 min (1 min to inject and then 2 min of pause before moving to the next site). As a result, the duration of the infusion procedure ranged between 20 and 40 min.

In Mk-C-A-SL, a third inactivation session took place, in which muscimol was infused in M1, targeting a few ICMS sites representing digits in the transition zone toward PMd (referred to as “M1 penumbra” session). A total volume of 9 μl muscimol was infused at nine sites along nine syringe penetrations.